An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study.
The Lancet Neurology.
Times cited: 207
Expanding the spectrum of monoclonal light chain deposition disease in muscle.
Inflammation in Parkinson's Disease: Scientific and Clinical Aspects.
Times cited: 3